Cellectis S.A.
PAR: ALCLS.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andre Choulika
- Employees
- 216
- Headquarters
- Paris, France
- IPO year
- 2007
- Market cap
- €231.3M
- Website
- https://www.cellectis.com
Loading ALCLS…
Loading profile data…Frequently asked questions about ALCLS
What does Cellectis S.A. (ALCLS.PA) do?
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
Where does ALCLS.PA trade?
Cellectis S.A. (ALCLS.PA) trades on the Euronext Paris.
What sector is ALCLS.PA in?
Cellectis S.A. (ALCLS.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cellectis S.A.?
Andre Choulika is the chief executive officer of Cellectis S.A. (ALCLS.PA).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in France.
Does ALCLS.PA pay a dividend?
Cellectis S.A. (ALCLS.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALCLS.PA go public?
Cellectis S.A. (ALCLS.PA) completed its initial public offering in 2007.